Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

A simple model of HIV epidemic in Italy: The role of the antiretroviral treatment

1. Istituto di Analisi dei Sistemi ed Informatica 'A. Ruberti' -CNR, Roma, Italy
2. Dipartimento di Scienze Biomediche e Cliniche 'L. Sacco', Sezione di Malattie Infettive e Immunopatologia, Università degli Studi di Milano, Milano, Italy

In the present paper we propose a simple time-varying ODE model to describe the evolution of HIV epidemic in Italy. The model considers a single population of susceptibles, without distinction of high-risk groups within the general population, and accounts for the presence of immigration and emigration, modelling their effects on both the general demography and the dynamics of the infected subpopulations. To represent the intra-host disease progression, the untreated infected population is distributed over four compartments in cascade according to the CD4 counts. A further compartment is added to represent infected people under antiretroviral therapy. The per capita exit rate from treatment, due to voluntary interruption or failure of therapy, is assumed variable with time. The values of the model parameters not reported in the literature are assessed by fitting available epidemiological data over the decade $2003 \div 2012$. Predictions until year 2025 are computed, enlightening the impact on the public health of the early initiation of the antiretroviral therapy. The benefits of this change in the treatment eligibility consist in reducing the HIV incidence rate, the rate of new AIDS cases, and the rate of death from AIDS. Analytical results about properties of the model in its time-invariant form are provided, in particular the global stability of the equilibrium points is established either in the absence and in the presence of infected among immigrants.

  Figure/Table
  Supplementary
  Article Metrics

Keywords HIV epidemic; HAART; immigration; emigration; epidemic ODE models; stability of equilibrium points

Citation: Federico Papa, Francesca Binda, Giovanni Felici, Marco Franzetti, Alberto Gandolfi, Carmela Sinisgalli, Claudia Balotta. A simple model of HIV epidemic in Italy: The role of the antiretroviral treatment. Mathematical Biosciences and Engineering, 2018, 15(1): 181-207. doi: 10.3934/mbe.2018008

References

  • [1] M. Arcà,C. A. Perucci,T. Spadea, The epidemic dynamics of HIV-1 in Italy: Modelling the interaction between intravenous drug users and heterosexual population, Stat Med, 11 (1992): 1657-1684.
  • [2] S. M. Blower,H. B. Gershengorn,R. M. Grant, A tale of two futures: HIV and antiretroviral therapy in San Francisco, Science, 287 (2000): 650-654.
  • [3] C. Bonifazi,F. Heins,S. Strozza,M. Vitiello, The italian transition from emigration to immigration country, IRPPS Working Papers, 24 (2009): 2-91.
  • [4] L. Camoni,S. Boros,V. Regine,M. Ferri,M. Santaquilani, Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2012, Notiziario Istituto Superiore di Sanitá, 26 (2013): 3-47.
  • [5] L. Camoni,S. Boros,V. Regine,M. Santaquilani,M. Ferri, Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2013, Notiziario Istituto Superiore di Sanitá, 27 (2014): 3-46.
  • [6] L. Camoni,M. Raimondo,M. Dorrucci,V. Regine,M. C. Salfa, Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy, AIDS Res Hum Retrov, 31 (2015): 282-287.
  • [7] L. Camoni, V. Regine, K. Stanecki, M. C. Salfa and M. Raimondo et al. , Estimates of the number of people living with HIV in Italy, Biomed Res Int, 2014 (2014), Article ID 209619, 6 pages.
  • [8] N. Crepaz,T. A. Hart,G. Marks, Highly active antiretroviral therapy and sexual risk behavior: A meta-analytic review, JAMA-J Am Med Assoc, 292 (2004): 224-236.
  • [9] O. Diekmann,J. A. P. Heesterbeek,J. A. J. Metz, On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations, J Math Biol, 28 (1990): 365-382.
  • [10] D. Donnell,J. M. Baeten,J. Kiarie,K. K. Thomas,W. Stevens, Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis, Lancet, 375 (2010): 2092-2098.
  • [11] J. Eaton,N. Menzies,J. Stover,V. Cambiano,L. Chindelevitch, Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models, Lancet Glob Health, 2 (2014): e23-e34.
  • [12] M. Franzetti,F. Adorni,C. Parravicini,B. Vergani,S. Antinori, Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: A single-institution retrospective study before and after the introduction of HAART, J Acquir Immune Defic Syndr, 62 (2013): 414-420.
  • [13] M. Franzetti, M. Violin, A. Antinori, A. De Luca and F. Ceccherini-Silberstein et al. , Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy, BMC Infect Dis, 14 (2014), p398.
  • [14] R. Granich, S. Crowley, M. Vitoria, Y. R. Lo and Y. Souteyrand et al. , Highly active antiretroviral treatment for the prevention of HIV transmission, J Int AIDS Soc, 13 (2010), 1pp.
  • [15] R. M. Granich,C. F. Gilks,C. Dye,K. M. De Cock,B. G. Williams, Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model, Lancet, 373 (2009): 48-57.
  • [16] H. Guo,M. Y. Li, Impacts of migration and immigration on disease transmission dynamics in heterogeneous populations, Discret Contin Dyn S -Series B, 17 (2012): 2413-2430.
  • [17] H. Guo,M. Y. Li,Z. Shuai, Global stability of the endemic equilibrium of multigroup SIR epidemic models, Canad Appl Math Quart, 14 (2006): 259-284.
  • [18] H. Guo,M. Y. Li,Z. Shuai, Global dynamics of a general class of multistage models for infectious diseases, SIAM J Appl Math, 72 (2012): 261-279.
  • [19] M. Iannelli,F. Milner,A. Pugliese,M. Gonzo, The HIV/AIDS epidemics among drug injectors: A study of contact structure through a mathematical model, Math Biosci, 139 (1997): 25-58.
  • [20] S. C. Kalichman,L. Eaton,D. Cain,C. Cherry,H. Pope, HIV treatment beliefs and sexual transmission risk behaviors among HIV positive men and women, J Behav Med, 29 (2006): 401-410.
  • [21] M. Kretzschmar,M. Schim van der Loeff,P. Birrell,D. De Angelis,R. Coutinho, Prospects of elimination of HIV with test-and-treat strategy, Proc Natl Acad Sci USA, 110 (2013): 15538-15543.
  • [22] J. R. Lingappa, J. P. Hughes, R. S. Wang, J. M. Baeten and C. Celum et al. , Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk, PLoS One, 5 (2010), e12598.
  • [23] P. M. Luz, B. Grinsztejn, L. Velasque, A. G. Pacheco and V. G. Veloso et al. , Long-term CD4 + cell count in response to combination antiretroviral therapy, PLoS One, 9 (2014), e93039.
  • [24] K. A. Lythgoe,L. Pellis,C. Fraser, Is HIV short-sighted? Insights from a multistrain nested model, Evolution, 67 (2013): 2769-2782.
  • [25] R. Manfredi,L. Calza,F. Chiodo, HIV disease among immigrants coming to Italy from outside of the European Union: A case-control study of epidemiological and clinical features, Epidemiol Infect, 127 (2001): 527-533.
  • [26] R. May,R. Anderson, Transmission dynamics of HIV infection, Nature, 326 (1987): 137-142.
  • [27] V. Miller,C. A. Sabin,A. N. Phillips,C. Rottmann,H. Rabenau, The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load, AIDS, 14 (2000): 2129-2136.
  • [28] F. Nyabadza,Z. Mukandavire,S. Hove-Musekwa, Modelling the HIV/AIDS epidemic trends in South Africa: Insights from a simple mathematical model, Nonlinear Anal Real World Appl, 12 (2011): 2091-2104.
  • [29] P. Paci, F. Martini, M. Bernaschi, G. D'Offizi and F. Castiglione, Timely HAART initiation may pave the way for a better viral control, BMC Infect Dis, 11 (2011), p56.
  • [30] M. Parczewski,M. Leszczyszyn-Pynka,M. Witak-Jedra,K. Maciejewska,W. Rymer, Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from poland differs by transmission category and subtype, J Antimicrob Chemother, 70 (2015): 233-242.
  • [31] V. Patruno, M. Venturi and S. Roberto, Intercensal Population Estimates. Demographic Balance, National Institute of Statistics of Italy (ISTAT), http://demo.istat.it/index.html.
  • [32] T. C. Quinn,M. J. Wawer,N. Sewankambo,D. Serwadda,C. Li, Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group, N Engl J Med, 343 (2000): 921-929.
  • [33] A. S. Rao,K. Thomas,K. Sudhakar,P. K. Maini, HIV/AIDS epidemic in India and predicting the impact of the national response: mathematical modeling and analyis, Math Biosci Eng, 6 (2009): 779-813.
  • [34] R. J. Smith,J. T. Okano,J. S. Kahn,E. N. Bodine,S. Blower, Evolutionary dynamics of complex networks of HIV drug-resistant strains: The case of San Francisco, Science, 327 (2010): 697-701.
  • [35] T. Sterling,R. E. Chaisson,R. D. Moore, HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy, AIDS, 15 (2001): 2251-2257.
  • [36] B. Taiwo,R. L. Murphy,C. Katlama, Novel antiretroviral combinations in treatment-experienced patients with HIV infection: Rationale and results, Drugs, 70 (2010): 1629-1642.
  • [37] The INSIGHT START Study Group,J. D. Lundgren,A. G. Babiker,F. Gordin,S. Emery, Initiation of antiretroviral therapy in early asymptomatic HIV infection, N Engl J Med, 373 (2015): 795-807.
  • [38] P. van den Driessche,J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math Biosci, 180 (2002): 29-48.
  • [39] J. Vercauteren,A. M. Wensing,D. A. van de Vijver,J. Albert,C. Balotta, Transmission of drug-resistant HIV-1 is stabilizing in europe, J Infect Dis, 200 (2009): 1503-1508.
  • [40] R. Weber,M. Ruppik,M. Rickenbach,A. Spoerri,H. Furrer, Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study, HIV Med, 14 (2013): 195-207.
  • [41] When To Start Consortium,J. A. Sterne,M. May,D. Costagliola,F. de Wolf, Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies, Lancet, 373 (2009): 1352-1363.
  • [42] WHO Guidelines Approved by the Guidelines Review Committee, Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV, World Health Organization, Geneva, 2015.
  • [43] D. P. Wilson,M. G. Law,A. E. Grulich,D. A. Cooper,J. M. Kaldor, Relation between HIV viral load and infectiousness: A model-based analysis, Lancet, 372 (2008): 314-320.
  • [44] T. Zhang,M. Jia,H. Luo,Y. Zhou,N. Wang, Study on a HIV/AIDS model with application to Yunnan province, China, Appl Math Model, 35 (2011): 4379-4392.
  • [45] M. Zwahlen and M. Egger, Progression and Mortality of Untreated HIV-positive Individuals Living in Resource-Limited Settings: Update of Literature Review and Evidence Synthesis, Report to UNAIDS obligation no HQ/05/422204.

 

Reader Comments

your name: *   your email: *  

© 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved